Eurofins Scientific SEHAM:ESF0 +2.80%87 PB Ratio is 2.60 as of Jun. 25, 2026, which is 13% below its 10-year median of 2.99. GuruFocus rates HAM:ESF0 with a GF Score™ of 87/100 and a GF Value™ of €66.78 (Fairly Valued). The stock has 6 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 61.73% on this metric.
Eurofins Scientific SE stock PB Ratio (=2.61) is close to 3-year high of 2.8.
The historical rank and industry rank for Eurofins Scientific SE's PB Ratio or its related term are showing as below:
HAM:ESF0'
s PB Ratio Range Over the Past 10 Years
Min: 1.65 Med: 2.99 Max: 6.93
Current: 2.61
During the past 13 years, Eurofins Scientific SE's highest PB Ratio was 6.93. The lowest was 1.65. And the median was 2.99.
HAM:ESF0's PB Ratio is ranked worse than 61.73% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs HAM:ESF0: 2.61
During the past 12 months, Eurofins Scientific SE's average Book Value Per Share Growth Rate was -10.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Eurofins Scientific SE was 55.20% per year. The lowest was 1.20% per year. And the median was 18.10% per year.
Back to Basics: PB Ratio
Eurofins Scientific SE (HAM:ESF0) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Eurofins Scientific SE (HAM:ESF0) has a PB Ratio of 2.60 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eurofins Scientific SE and its competitors. This is 13% below median its historical median of 2.99. Over the past decade, Eurofins Scientific SE's PB Ratio has ranged from 1.65 to 6.93. According to the industry distribution chart, Eurofins Scientific SE ranks #121 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 61.7%.
Is Eurofins Scientific SE's PB Ratio too high?
Eurofins Scientific SE's current PB Ratio of 2.60 is 13% below median its 10-year median of 2.99. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 6.93. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Eurofins Scientific SE's value of 2.60 is 26.8% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #121 out of 196 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #121 out of 196 companies for PB Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median PB Ratio is 2.05. Eurofins Scientific SE's value of 2.60 is 26.8% above this benchmark. Historically, Eurofins Scientific SE's own PB Ratio has ranged from 1.65 to 6.93 over the past decade. While the company's 10-year median is 2.99 vs. the industry median of 2.05, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current PB Ratio of 2.60 is 26.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current PB Ratio is 2.60, which is 13% below median its own 10-year median of 2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (HAM:ESF0) is currently considered Fairly Valued. The stock's GF Value™ is €66.78, compared to a current price of €66.88 — trading 0.1% above its estimated fair value. The current PB Ratio is 2.60, which is 13% below median its 10-year median of 2.99 and 26.8% above the Medical Diagnostics & Research industry median of 2.05. Eurofins Scientific SE's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (HAM:ESF0), the current PB Ratio is 2.60 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (HAM:ESF0) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of €66.88 is trading 0.1% above its estimated GF Value™ of €66.78.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for HAM:ESF0:
PB Ratio: 2.60 (13% below median its 10-year median of 2.99)
GF Value™: €66.78 vs. price of €66.88 (0.1% above fair value)
Industry Position: 26.8% above the Medical Diagnostics & Research median (#121 of 196)
No single metric tells the full story. See the HAM:ESF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
87GF Score
Get the complete analysis for HAM:ESF0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:ESF0 has been successfully added to your 
